Manassas, Virginia – Stromatis Pharma announces an exciting deal with Caerus Therapeutics, allowing Stromatis Pharma exclusive rights to utilize Caerus Therapeutics’ innovative and proprietary antibody-discovery platform for the discovery of ten novel antibodies. Caerus Therapeutics’ platform, referred to as Differential Immunization for Antibody and Antigen Discovery (DIAAD), is combined with a synthetic lymph node mimetic (LNM/VLN) to develop antibodies with dramatically increased specificity. Stromatis Pharma’s suite of antibodies, generated utilizing this platform, exhibit low or no binding to normal tissue, positioning them as superior immuno-oncology drugs with high & selective tumor-killing impact.
Stromatis Pharma is a private biotech company located in Prince William County’s Innovation Park, Manassas, VA. Stromatis Pharma is committed to developing therapeutics for patients with difficult-to-treat cancers. The team at Stromatis Pharma is devoted to the mission of creating a portfolio of superior and highly specific immunotherapies.
Stromatis Pharma Contact:
Guy Yachin, MBA
(301) 633-0393
guy.yachin@gmail.com
Source: Stromatis Pharma, Inc.
